Anti-androgenic treatment of obsessive-compulsive disorder: an open-label clinical trial of the long-acting gonadotropin-releasing hormone analogue triptorelin

Int Clin Psychopharmacol. 2007 Jan;22(1):57-61. doi: 10.1097/01.yic.0000224793.51900.cb.


Some case reports have shown that patients suffering from obsessive-compulsive disorder can be effectively treated with anti-androgenic pharmacological agents with various modes of action. The most effective group of such agents is the long-acting analogues of the gonadotropin-releasing hormone. This investigation was undertaken in order to further elucidate the possibility of using such powerful anti-androgenic agents in the treatment of obsessive-compulsive disorder. Six male patients, all suffering from therapy-resistant obsessive-compulsive disorder, were included in a 48 weeks open-label trial of the long-acting GnRH-analogue triptorelin. Every other week, the patients rated the severity of obsessive-compulsive disorder symptoms by means of a visual analogue scale. During the course of the trial, five out of six patients experienced a considerable improvement. The finding gives further support to the contention that anti-androgenic agents are effective in the treatment of obsessive-compulsive disorder.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Androgen Antagonists / therapeutic use*
  • Antipsychotic Agents / therapeutic use*
  • Gonadotropin-Releasing Hormone / analogs & derivatives
  • Gonadotropin-Releasing Hormone / therapeutic use*
  • Humans
  • Luteinizing Hormone / blood
  • Male
  • Middle Aged
  • Obsessive-Compulsive Disorder / blood
  • Obsessive-Compulsive Disorder / drug therapy*
  • Obsessive-Compulsive Disorder / psychology
  • Psychiatric Status Rating Scales
  • Time Factors
  • Treatment Outcome
  • Triptorelin Pamoate / therapeutic use*


  • Androgen Antagonists
  • Antipsychotic Agents
  • Triptorelin Pamoate
  • Gonadotropin-Releasing Hormone
  • Luteinizing Hormone